Regulatory change leads the cannabis agenda, with Thailand advancing legislation that could sharply reduce its recreational-facing market and Maryland proposing new compliance requirements across licensing, advertising and product sales. In cannabis business news, Canopy Growth is extending its international medical portfolio into the United Kingdom.
Thailand Cabinet Approves Medical-Only Cannabis Bill
Thailand’s cabinet approved draft legislation on September 22 that would restrict cannabis use to medical treatment and research. The bill now moves to the House of Representatives for consideration.
The proposed framework would require three-year licenses for cultivation, production, import, export and sales while introducing grower registration, supply-chain tracking and tougher penalties. It would also restrict advertising and sales to people younger than 20, pregnant women and breastfeeding women.
Existing dispensaries can continue operating under their current licenses, but operators face substantial conversion pressure as those licenses expire. The legislation is the government’s latest attempt to replace the regulatory gaps that followed Thailand’s 2022 decriminalization policy with a tightly controlled medical market.
Why It Matters: If enacted, the bill could force a major consolidation of Thailand’s cannabis sector and significantly change the economics of dispensaries, cultivation businesses and international suppliers. Analysis: Because parliamentary approval is still required, businesses should treat the cabinet decision as a consequential policy advance rather than a completed market transition.
Source: Nation Thailand
Maryland Proposes Broad Cannabis Compliance Overhaul
The Maryland Cannabis Administration released draft amendments affecting license renewals, ownership transfers, advertising, employee training, packaging and product sales. Informal stakeholder comments are due September 30, with a separate formal comment period expected after publication in the Maryland Register.
Under the proposal, regulators could deny license renewals when an operator owes taxes in any jurisdiction and rescind conditional licenses when applicants fail to respond to official communications within 30 days. The amendments would also increase the employee limit for micro dispensaries from 10 to 20 and establish additional review requirements for license ownership transfers.
Other provisions would create a process for documenting advertising audience composition, replace responsible-vendor training with a cannabis-agent training program and expressly prohibit sales of expired, adulterated or otherwise noncompliant products.
Why It Matters: The package links tax compliance, workforce rules, advertising evidence and product controls directly to operators’ ability to maintain licenses. Analysis: Maryland businesses may need to review tax exposure, training systems and marketing documentation before the amendments enter the formal rulemaking stage.
Source: Maryland Cannabis Administration
Canopy Growth Enters UK Medical Cannabis Market
Canopy Growth announced that it will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom, expanding the company’s international medical business into another European market.
GROW Group U.K. will commercialize the products under Canopy’s Spectrum Therapeutics medical brand. The companies did not disclose financial terms or a detailed sales forecast.
Why It Matters: The agreement gives Canopy an additional channel for Canadian production and strengthens its position in Europe’s expanding prescription cannabis sector. Analysis: The deal’s ultimate financial importance will depend on patient adoption, pricing and Canopy’s ability to build sustained volume through GROW Group’s distribution network.
Source: Canopy Growth
What We’re Watching
Over the next 24 to 72 hours, watch for parliamentary reaction to Thailand’s cannabis bill, industry responses to Maryland’s September 30 comment deadline and additional details about the timing and commercial scale of Canopy’s UK rollout. Regulatory decisions emerging from Alaska’s September 22 special cannabis board meeting also warrant monitoring as official records become available.
